| CARTESIAN THERAPEUTICS |
| USA |
| Gesundheit |
| US8162123025 / A407YS |
| 1S70 (Frankfurt) / RNAC (NASDAQ) |
| FRA:1S70, ETR:1S70, 1S70:GR, NASDAQ:RNAC |
| - |
| https://www.cartesianther.. |
|
Cartesian Therapeutics Inc. is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. It utilizes its proprietary ImmTOR immune tolerance platform to induce antigen-specific immunity and mitigate unw..
>Volltext.. |
| 146.75 Mio. EUR |
| 51.04 Mio. EUR |
| 2.42 Mio. EUR |
| -72.55 Mio. EUR |
| -112.88 Mio. EUR |
| -4.34 EUR |
| 10.98 Mio. EUR |
| 108.41 Mio. EUR |
| -64.06 Mio. EUR |
| 8.38 |
| -89.89% |
| 52.4% |
| - |
| - |
| - |
| - |
| CARTESIAN |
| 04.04.26 |